DK1043026T3 - Melanombehandling - Google Patents

Melanombehandling

Info

Publication number
DK1043026T3
DK1043026T3 DK00107101T DK00107101T DK1043026T3 DK 1043026 T3 DK1043026 T3 DK 1043026T3 DK 00107101 T DK00107101 T DK 00107101T DK 00107101 T DK00107101 T DK 00107101T DK 1043026 T3 DK1043026 T3 DK 1043026T3
Authority
DK
Denmark
Prior art keywords
melanoma treatment
melanoma
treatment
Prior art date
Application number
DK00107101T
Other languages
Danish (da)
English (en)
Inventor
Mary Ellen Rybak
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1043026T3 publication Critical patent/DK1043026T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DK00107101T 1999-04-08 2000-04-06 Melanombehandling DK1043026T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28836699A 1999-04-08 1999-04-08
EP00107101A EP1043026B1 (de) 1999-04-08 2000-04-06 Melanoma Therapie

Publications (1)

Publication Number Publication Date
DK1043026T3 true DK1043026T3 (da) 2005-07-04

Family

ID=23106795

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00107101T DK1043026T3 (da) 1999-04-08 2000-04-06 Melanombehandling
DK05002951T DK1535622T3 (da) 1999-04-08 2000-04-06 Melanomterapi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05002951T DK1535622T3 (da) 1999-04-08 2000-04-06 Melanomterapi

Country Status (22)

Country Link
EP (3) EP1043026B1 (de)
JP (1) JP2000319195A (de)
CN (1) CN1390132A (de)
AR (1) AR023398A1 (de)
AT (3) ATE496631T1 (de)
AU (1) AU771569B2 (de)
BR (1) BR0009646A (de)
CA (1) CA2303992A1 (de)
CO (1) CO5170404A1 (de)
CY (1) CY1108922T1 (de)
DE (3) DE60041290D1 (de)
DK (2) DK1043026T3 (de)
ES (2) ES2319776T3 (de)
HK (2) HK1032349A1 (de)
HU (1) HU230057B1 (de)
MY (1) MY126763A (de)
NO (1) NO328111B1 (de)
PE (1) PE20010027A1 (de)
PT (2) PT1535622E (de)
TW (1) TWI292320B (de)
WO (1) WO2000061175A2 (de)
ZA (1) ZA200108173B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates

Also Published As

Publication number Publication date
AR023398A1 (es) 2002-09-04
BR0009646A (pt) 2002-02-05
CA2303992A1 (en) 2000-10-08
EP1043026A2 (de) 2000-10-11
EP2025344A1 (de) 2009-02-18
EP2025344B1 (de) 2011-01-26
EP1535622A1 (de) 2005-06-01
CN1390132A (zh) 2003-01-08
AU771569B2 (en) 2004-03-25
AU4204600A (en) 2000-11-14
DK1535622T3 (da) 2009-04-20
CO5170404A1 (es) 2002-06-27
DE60020444T2 (de) 2006-05-04
PE20010027A1 (es) 2001-02-05
DE60045591D1 (de) 2011-03-10
JP2000319195A (ja) 2000-11-21
ES2239954T3 (es) 2005-10-16
NO20014852D0 (no) 2001-10-05
HU230057B1 (hu) 2015-06-29
ATE496631T1 (de) 2011-02-15
DE60041290D1 (de) 2009-02-12
PT1535622E (pt) 2009-03-19
ES2319776T3 (es) 2009-05-12
ATE296639T1 (de) 2005-06-15
HK1075416A1 (en) 2005-12-16
HUP0200775A3 (en) 2002-09-30
EP1535622B1 (de) 2008-12-31
EP1043026A3 (de) 2000-12-20
MY126763A (en) 2006-10-31
ATE419001T1 (de) 2009-01-15
DE60020444D1 (de) 2005-07-07
WO2000061175A2 (en) 2000-10-19
ZA200108173B (en) 2003-01-06
TWI292320B (en) 2008-01-11
EP1043026B1 (de) 2005-06-01
CY1108922T1 (el) 2014-07-02
HUP0200775A2 (en) 2002-08-28
PT1043026E (pt) 2005-09-30
WO2000061175A3 (en) 2001-02-01
NO20014852L (no) 2001-12-06
NO328111B1 (no) 2009-12-07
HK1032349A1 (en) 2001-07-20

Similar Documents

Publication Publication Date Title
DE69924365D1 (de) Massagegerät
DE60022582D1 (de) Busspannungsregelungsschaltung
DE122007000064I2 (de) Erythropoietinkonjugate
DE10084676T1 (de) Einmallanzettvorrichtung
ATA51899A (de) Handstempel
FI20000863A (fi) Uusi hoitomenetelmä
NO20020487D0 (no) 2-Pyrazolin-5-oner
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
NO20013337D0 (no) Ny behandling
FI990377A0 (fi) Profiilikiskoliitos
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE69916133D1 (de) Elektro-neuro-adaptiver stimulator
ITMI991895A0 (it) Depigmentanti cutanei
FI19991829A (fi) Uintianalysaattori
DE10082008D2 (de) Ausbeulgerät
ATE269311T1 (de) Benzoylpyridazine
DK1043026T3 (da) Melanombehandling
ATE440824T1 (de) Nitro-sulfobenzamide
ATA107599A (de) Heizwasserbereiter
NO20022478L (no) Arbeidsplassmöbel
DE10085167T1 (de) Gangumschalteinrichtung
ATA203199A (de) Ablauf
AT500658A3 (de) Isolierplatte
DE10085144T1 (de) Polypeptidkomposition